The American Journal of #ManagedCare is a peer-reviewed, indexed publication. AJMC.com offers news in health policy, disease states, and managed care.
Cranbury, NJ
- Tweets 45,406
- Following 888
- Followers 7,114
- Likes 2,369
That’s a wrap on PCOC2026 in Nashville!
Until next time, thank you for being part of the conversation.
44
Great conversations don’t always end when the sessions do.
Thank you to everyone who joined us for a full day of insights and discussion. We’ll see you tomorrow for Day 2.
126
Day 1 of Patient-Centered Oncology Care® is well underway in Nashville!
It’s been a pleasure learning and connecting with everyone joining us today, and there’s still plenty more to come. We hope you’re enjoying #PCOC26 as much as we are!
87
Nonadherence to #semaglutide for #obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults, according to a new research letter.
Learn more here: hubs.li/Q04y9LvZ0
98
The #PCOC2026MainEvent kicks off tomorrow!
In a recent interview, Stephen "Fred" Divers, MD, previewed the meeting, including his session on the Oncology Care Index and the gap in #AI adoption in oncology.
Watch here: hubs.li/Q04y9L3S0
104
FACT accreditation: safeguard or access bottleneck?
Tara Graff, DO, MS, details what accreditation demands. Debra Patt, MD, PhD, MBA, argues it shouldn't be rate-limiting—payers, not FACT, are often the real barrier to CAR T access.
New Episode: hubs.li/Q04wCgb60
106
Bundled payment models offer #employers and #communityoncology practices greater cost predictability while improving patient access, Robert Baird, RN, MSA, said at the Community Oncology Alliance Payer Exchange & Innovation Summit.
Watch here: hubs.li/Q04xVKV60
156
No head-to-head trial for #vitiligo #JAKinhibitors—so what can payers compare?
In this video, experts discuss why timepoints must align (50% vs 25% at 1 year, but different populations), plus how member churn shapes #payer coverage.
Watch Here: hubs.li/Q04xHF_D0
1
174
After a #TNFinhibitor falls short in rheumatoid arthritis, should clinicians switch within the class or change mechanisms?
SELECT-SWITCH offers new data that could inform that decision
Explore the Findings: hubs.li/Q04xBwqk0
#RheumatoidArthritis #ManagedCare #Rheumatology
102
Leaders from Tennessee Oncology will explore practical perspectives and lessons learned from developing a community-based cellular therapy program on September 30.
Register for the free webinar: hubs.li/Q04xBzfC0
#CommunityOncology #CellularTherapy #ManagedCare
121
How do the 2 FDA-approved therapies for Alzheimer disease agitation compare?
Experts break down the clinical trial data, safety findings, and evidence on reducing agitation and preventing relapse.
Watch Now: hubs.li/Q04sFNq30
#Alzheimer #Neurology
66
$25.5 billion in potential Medicare savings. What could it mean for drug prices worldwide?
Unlock the full analysis: hubs.li/Q04xphd80
60
Lung transplant candidates are aging rapidly, while #cysticfibrosis decline in children shifts pediatric transplant toward sicker, more complex patients, experts highlighted at #ERS2026.
Learn more here: hubs.li/Q04x1SzH0
132
In an interview with #AJMC during #ERS2026, Francesca Puggioni, MD, explained how multidisciplinary teams choose #COPD biologics and why systemic inflammation matters as much as FEV1.
Watch here: hubs.li/Q04x1RyX0
116
Patient-reported outcomes may offer a useful way to identify patients with chronic lymphocytic leukemia (#CLL) or small lymphocytic leukemia (#SLL) who are at higher risk for poor survival and serious treatment-related adverse events.
Learn more here: hubs.li/Q04x1FXH0
119
Dermatologist Angela Lamb, MD, explores LEVEL UP switching data, #JAK inhibitor options, and what’s needed to move advanced #AtopicDermatitis therapies earlier in treatment.
Watch Here: hubs.ly/Q04sbh4n0 #Dermatology
136
Sequencing therapy for R/R #multiplemyeloma is getting more complex as more options become available. Dr Amandeep Godara of @huntsmancancer breaks down patient factors, rural access barriers, and why treatment is becoming more individualized.
Watch here: hubs.li/Q04wLsb40
120
Should people be able to bet on whether a drug earns FDA approval?
AJMC® spoke with bioethics experts about the potential risks prediction markets pose to drug development, clinical trial integrity, and public trust.
Sign in to gain access: hubs.li/Q04wLZjb0
101
The barrier to better #RetinaCare isn’t the science. It’s #ReimbursementGaps, OR availability, and out-of-pocket costs—experts say that’s the one problem the field hasn’t been able to fix.
Read More on Gene Therapy, #TKIs, and What’s Next: hubs.li/Q04v-gXm0
96
$8.6 billion a year. That’s how much extending Most Favored Nation pricing across 82 high-spending brand-name drugs could save Medicaid, according to recent research.
Now, the drug pricing strategy is expanding.
Unlock the full analysis: hubs.li/Q04wykWP0
102